The size of the Bipolar Disorder Market was valued at around USD 0.80 billion in 2021. This value is estimated to grow at a CAGR of 2.12% to reach USD 0.88 billion by 2026.
Growing incidence of bipolar disorders, unmet medical needs, strong pipeline drugs organized by pharmaceutical industries an unhealthy lifestyle of people is majorly increasing the growth of the market in the European region. An estimated 46 million people are diagnosing bipolar disorders globally, in which 52% of males and 48% are female. Technological advancements, a growing number of initiatives taken by the European governments to create awareness among people, and rising government support through funds and investments are positive signals co-operating to develop further. For instance, the introduction of the bipolar disorder phenomena database, sponsored by the National Institute of Mental Health (NIMH), provides full research information regarding the disorder's visible signs and complaints.
Insufficient amenities for bipolar disorder diagnosis, incapable equipment resulting in bipolar disorder, stringent government rules on misrecognition of the disorder, and inadequate equipment resulting in bipolar disorder being written as other personality disorder or depression. Rising adverse side-effects post to the usage of drugs during the treatment of disease, restraining the market growth in the region.
This research report on the European Bipolar Disorder Market has been segmented and sub-segmented into the following categories:
Regional Analysis:
Europe is next to North America to govern the global bipolar disorder market. It is predicted to hike at a prominent growth rate during the forecast period due to technological advancements, growing awareness associated with bipolar disorder, and healthcare infrastructure advancements.
Germany and the UK are expected to have notable growth from 2020 to 2025 due to the Y-O-Y increase in bipolar disorders. Technological advancements that have been used in developing genetic research on bipolar disorder and further augmenting the market Growing awareness related to bipolar disorders, a growing number of mergers and acquisitions among drug-producing companies fuel the market region. France, Italy, and Spain hold a significant share in the bipolar disorder market in Europe.
The increasing awareness about bipolar disorder and the region's developed healthcare infrastructure is expected to be the significant driver of market growth.
Lead players in the market are Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Otsuka Holdings Co. Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc and AbbVie, Inc
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Method
5.1.1 Introduction
5.1.2 Genotypic
5.1.3 Proteomics-based
5.1.4 Phenotypic
5.1.5 Y-o-Y Growth Analysis, By Method
5.1.6 Market Attractiveness Analysis, By Method
5.1.7 Market Share Analysis, By Method
5.2 Application
5.2.1 Introduction
5.2.2 F&B
5.2.3 Diagnostic
5.2.4 Pharmaceutical
5.2.5 Environmental
5.2.6 Y-o-Y Growth Analysis, By Application
5.2.7 Market Attractiveness Analysis, By Application
5.2.8 Market Share Analysis, By Application
5.3 Product
5.3.1 Introduction
5.3.2 Identification Services
5.3.3 Consumables
5.3.4 Instruments
5.3.5 Y-o-Y Growth Analysis, By Products and Services
5.3.6 Market Attractiveness Analysis, By Products and Services
5.3.7 Market Share Analysis, By Products and Services
5.4 End User
5.4.1 Food Manufacturing Industries
5.4.2 Pharmaceutical Companies
5.4.3 Hospitals and Diagnostic Centres
5.4.4 Other End users
5.3.5 Y-o-Y Growth Analysis, By End User
5.3.6 Market Attractiveness Analysis, By End User
5.3.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Method
6.1.3.3 By Application
6.1.3.4 By Product
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Method
6.1.4.3 By Application
6.1.4.4 By Product
6.1.4.5 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Method
6.1.5.3 By Application
6.1.5.4 By Product
6.1.5.5 By End user
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Shimadzu Corporation
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Dickinson & Company
8.3 Biolog Inc.
8.4 Merck KGaA
8.5 IEH Laboratories & Consulting Group
8.6 Trivitron Healthcare
8.7 Laboratory Corporation of America Holdings
8.8 Thermo Fisher Scientific Inc.
8.9 Bruker Corporation
8.10 Charles River Laboratories
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
